TABLE 9, Infliximab efficacy outcomes: uncontrolled follow-up data - Etanercept, Infliximab and Adalimumab for the Treatment of Psoriatic Arthritis: A Systematic Review and Economic Evaluation

Warning: The NCBI web site requires JavaScript to function. more...

Trial	Duration (weeks)	Outcomes		Infliximab/placebo
IMPACT⁷⁹^–⁸¹^,⁸⁹^,⁹⁶^,¹⁰⁹^,¹¹¹^,¹¹³^–¹¹⁵^,¹¹⁷^,¹¹⁸	50	ACR 20	All pts	34/49 (69.4%)
			+MTX	16/22 (72.7%)
			−MTX	18/27 (66.7%)
		ACR 50		26/49 (53.1%)
		ACR 70		19/49 (38.8%)
		PsARC		36/49 (73.5%)
		HAQ: mean (SD)% change from baseline		(n = 45) −42.5 (59.0)
		PASI 50^a		19/22 (86.3%)
		PASI 75^a		13/22 (59%)
		PASI 90^a		9/22 (40.9%)
		PASI: mean (SD) change from baseline^a		(n = 35) −4.8 (5.9)
		Total modified van der Heijde–Sharp score: mean (SD) change from baseline		(n = 70) −1.72 (5.82)
IMPACT 2⁸²^,⁹⁰^,⁹¹^,⁹⁵^,⁹⁸^,¹⁰⁶^,¹¹²^,¹¹⁶	54	PsARC		67/90 (74.4%)
		PASI 50^a		57/82 (69.5%)
		PASI 75^a		40/82 (48.8%)
		PASI 90^a		32/82 (39%)
		Total modified van der Heijde–Sharp score: mean (SD) change from baseline		Infliximab/infliximab −0.94 (3.4) Placebo/infliximab 0.53 (2.6)

: pts, patients.
a: PASI 50/75/90 outcomes are for subgroup of patients with ≥ 3% BSA psoriasis.

Etanercept, Infliximab and Adalimumab for the Treatment of Psoriatic Arthritis: A Systematic Review and Economic Evaluation.

Health Technology Assessment, No. 15.10.

Rodgers M, Epstein D, Bojke L, et al.

Southampton (UK): NIHR Journals Library; 2011 Feb.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.